Ocular Therapeutix to Present Key Data at Major Retina Conferences
Event summary
- Ocular Therapeutix will present Phase 3 trial results for AXPAXLI (OTX-TKI) at The Retina Society and Euretina Congress in September and October 2026.
- CEO Pravin U. Dugel to participate in a fireside chat at Baird's Global Healthcare Conference on September 15, 2026.
- Company to host investor meetings at Wells Fargo's Healthcare Conference on September 10, 2026.
- AXPAXLI is in Phase 3 trials for wet AMD and diabetic retinal disease, leveraging ELUTYX hydrogel technology.
The big picture
Ocular Therapeutix's participation in these conferences underscores the strategic importance of its AXPAXLI program, which could redefine treatment paradigms for retinal diseases. The company's focus on sustained drug delivery via its ELUTYX technology aligns with broader industry trends toward longer-acting therapies in ophthalmology. Success in these trials could significantly enhance its competitive position in the retinal disease market.
What we're watching
- Clinical Validation
- Whether AXPAXLI's Phase 3 trial results will position it as a competitive treatment for wet AMD and diabetic retinal disease.
- Investor Sentiment
- How investor meetings and conference presentations will impact Ocular Therapeutix's market valuation.
- Regulatory Pathway
- The pace at which Ocular Therapeutix advances AXPAXLI through regulatory approvals following positive trial data.